Cervical Cancer Screening.
Journal Article (Journal Article;Review)
Cervical cancer screening in the United States has accompanied profound decreases in cancer incidence and mortality over the last half century. Two screening strategies are currently endorsed by US-based guideline groups: (1) triennial cytology for women aged 21 to 65 years, and (2) triennial cytology for women aged 21 to 29 years followed by cytology plus testing for high-risk human papillomavirus types every 5 years for women aged 30 years and older. Providing women with affordable, easily accessible screening, follow-up of abnormal tests, and timely treatment will result in the greatest impact of screening on cervical cancer incidence and mortality.
Full Text
Duke Authors
Cited Authors
- Sawaya, GF; Huchko, MJ
Published Date
- July 2017
Published In
Volume / Issue
- 101 / 4
Start / End Page
- 743 - 753
PubMed ID
- 28577624
Pubmed Central ID
- PMC6585416
Electronic International Standard Serial Number (EISSN)
- 1557-9859
Digital Object Identifier (DOI)
- 10.1016/j.mcna.2017.03.006
Language
- eng
Conference Location
- United States